Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-20 of 68
Keywords: Immunotherapy
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology 1–18.
Published Online: 11 November 2024
... was examined to gain insight into the tumor microenvironment (TME) in different cancers. The results of the bioinformatic analysis were validated using immunotherapy clinical trials and pathological specimens. CCK-8 and Transwell assay experiments were performed to investigate the biological function of ESCO2...
Journal Articles
Subject Area:
Oncology
Jianyu Xu, Ying Zhu, Qian Liu, Chenchang Xu, Wenjuan Wang, Jiantong Sun, Xinyuan Ding, Biao Liu, Lei Chen
Journal:
Oncology
Oncology 1–16.
Published Online: 07 November 2024
... TACC3 Pancancer Lung adenocarcinoma Immunotherapy Docetaxel resistance As a major public health issue, cancer continues to receive worldwide attention, and the morbidity of lung cancer remain high [ 1, 2 ]. The systematic therapy of NSCLC continues to evolve. The integrated medical...
Journal Articles
Subject Area:
Oncology
Rene Novysedlak, Miray Guney, Majd Al Khouri, Robin Bartolini, Lily Koumbas Foley, Iva Benesova, Andrej Ozaniak, Vojtech Novak, Stepan Vesely, Pavel Pacas, Tomas Buchler, Zuzana Ozaniak Strizova
Journal:
Oncology
Oncology 1–25.
Published Online: 09 October 2024
... complicates immunotherapy. Key Messages: The infiltration of cytotoxic CD8 + T cells and Th1 cells correlates with better outcomes, while elevated T regs and TAMs promote tumor growth, metastasis, and resistance. TANs and natural killer (NK) cells exhibit dual roles, with higher NK cell levels linked...
Journal Articles
Subject Area:
Oncology
Jingkai Zhou, Haihang Nie, Xiaoqiang Yang, Fan Wang, Panpan Yu, Yali Yu, Yumei Ning, Jun Lai, Haizhou Wang, Qiu Zhao, Fei Xu
Journal:
Oncology
Oncology (2024) 102 (12): 1041–1055.
Published Online: 24 July 2024
...Jingkai Zhou; Haihang Nie; Xiaoqiang Yang; Fan Wang; Panpan Yu; Yali Yu; Yumei Ning; Jun Lai; Haizhou Wang; Qiu Zhao; Fei Xu Introduction: As the primary members of the deubiquitinase family, ubiquitin-specific proteases can regulate the efficacy of immunotherapy and mediate immune evasion. However...
Journal Articles
Subject Area:
Oncology
Hidenari Nagai, Takanori Mukozu, Teppei Matsui, Kunihide Mohri, Hideki Nagumo, Naoyuki Yoshimine, Kojiro Kobayashi, Yu Ogino, Yasuko Daido, Noritaka Wakui, Koichi Momiyama, Takahisa Matsuda, Yoshinori Igarashi, Koji Higai
Journal:
Oncology
Oncology (2024) 102 (10): 828–840.
Published Online: 23 February 2024
... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Atezolizumab Bevacizumab Hepatocellular carcinoma Immunotherapy Regulatory T cells Programed cell death-ligand 1 Interleukin 6 Tumor...
Journal Articles
Subject Area:
Oncology
Takahito Sugase, Takashi Kanemura, Tomohira Takeoka, Norihiro Matsuura, Yasunori Masuike, Naoki Shinno, Hisashi Hara, Takeshi Omori, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai, Toshinori Sueda, Shinichiro Hasegawa, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Masayoshi Yasui, Hiroshi Miyata
Journal:
Oncology
Oncology (2024) 102 (6): 484–493.
Published Online: 05 December 2023
.... Early tumour shrinkage Depth of response Metastatic or unresectable oesophageal cancer Immunotherapy Pembrolizumab Oesophageal cancer ranks 10th among newly diagnosed cancers and 6th in cancer-related mortality worldwide [ 1 ]. Patients with oesophageal cancer generally undergo...
Journal Articles
Subject Area:
Oncology
Yang Li, Guodong Deng, Ning Liang, Pingping Hu, Yan Zhang, Lili Qiao, Yingying Zhang, Jian Xie, Hui Luo, Fei Wang, Fangjie Chen, Fengjun Liu, Deguo Xu, Jiandong Zhang
Journal:
Oncology
Oncology (2024) 102 (5): 382–398.
Published Online: 30 October 2023
... in PubMed, Embase, and Cochrane Library databases. We also reviewed abstracts of relevant conferences to prevent omissions. The meta-analysis was performed using Stata version 16.0. Results: CRT combined with immunotherapy can improve progression-free survival (PFS) (hazard rate [HR]: 0.60, 95% confidence...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (2024) 102 (5): 368–381.
Published Online: 12 October 2023
... was constructed to predict patient survival based on GCSH expression. Subsequently, Gene set variation analysis was used to explore the potential biological functions of GCSH in EC. The impact of GCSH on the tumor microenvironment (TME) was estimated. Finally, the effect of GCSH on the response to immunotherapy...
Journal Articles
Subject Area:
Oncology
Chrystal A. Landry, Julia Blanter, Meng Ru, Julie Fasano, Paula Klein, Theresa Shao, Aarti Bhardwaj, Amy Tiersten
Journal:
Oncology
Oncology (2024) 102 (1): 9–16.
Published Online: 18 August 2023
... with standard dose durvalumab had a favorable AE profile in patients with previously treated HER2− MBC and ROC. The early antitumor activity observed in all MBC patients enrolled in the study suggests that further investigation of this combination is warranted. Immunotherapy Metastatic breast cancer...
Journal Articles
Felicitas Hitz, Noémie Lang, Ulrich Mey, Walter Mingrone, Alden Moccia, Christian Taverna, Urban Novak, Frank Stenner, Adrian Schmidt, Christoph Mamot, Natalie Fischer, Paul M. Putora
Journal:
Oncology
Oncology (2023) 101 (3): 159–165.
Published Online: 07 March 2023
.... 2022 Hodgkin lymphoma Lymphoma Chemoimmunotherapy Systemic therapy Immunotherapy Decision-making Experts in the current decision-making analysis proposed prednisone, vinblastine, adriblastin, gemcitabine [ 28 ] or cyclophosphamide, adriblastin, vincristine, prednisone [ 29 ] for those...
Journal Articles
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Journal:
Oncology
Oncology (2023) 101 (5): 283–291.
Published Online: 19 January 2023
... with immunotherapy with so far conflicting results. These two studies have in common the fact that they have analyzed the data of patients treated with different immunotherapy drugs and in different lines of treatment. The first of these studies was published in 2020 and showed that serum albumin levels and PNI...
Journal Articles
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates)
,
Karger e-Journal Backfile Collection 2023
,
Oncology
Amber Draper, Emily H. Jung, Yichun Cao, Rami P. Atallah, Jeffrey Switchenko, Sujata Kane, Jessica Guadagno, Aaron T. Jones, Edith Brutcher, Olatunji B. Alese
Journal:
Oncology
Oncology (2023) 101 (4): 213–223.
Published Online: 10 January 2023
... shown a correlation between immune cell infiltration and poorly differentiated cancers. This study evaluated the impact of poorly differentiated histology on survival in patients with advanced gastrointestinal cancers treated with immunotherapy. Methods: This study was a retrospective, single-center...
Journal Articles
Subject Area:
Oncology
Li-Chun Lu, Cecilia Deantonio, Cintia C. Palu, Yi-Hsuan Lee, Laura S. Mitchell, Marianne Cowan, Matthew Corser, Lorcan Sherry, Ann-Lii Cheng, Sonia Quaratino, Yu-Yun Shao, Richard C.A. Sainson, Chih-Hung Hsu
Journal:
Oncology
Oncology (2022) 100 (8): 419–428.
Published Online: 16 June 2022
... receptor Tumor microenvironment Immunotherapy Immune checkpoint The standard of care for systemic therapy in advanced hepatocellular carcinoma (HCC) has been antiangiogenic agents for more than a decade. Sorafenib was first approved as the first-line therapy in 2007 [1, 2]. Other vascular...
Journal Articles
Subject Area:
Oncology
Walid Shalata, Alexander Yakobson, Sarah Weissmann, Elron Oscar, Muhammed Iraqi, Waleed Kian, Nir Peled, Abed Agbarya
Journal:
Oncology
Oncology (2022) 100 (9): 467–474.
Published Online: 09 June 2022
..., instructions or products referred to in the content or advertisements. Table 1. NSCLC patient demographics and disease characteristics C-MET Non-small cell lung cancer Crizotinib (Xalkori®) Tyrosine kinase inhibitors Immunotherapy Lung cancer remains the leading cause of cancer...
Journal Articles
Subject Area:
Oncology
Guang Yang, Takehiro Tanaka, Hideaki Kinugasa, Hiromitsu Kanzaki, Meng-Xi Chen, Koichi Ichimura, Masahiro Nakagawa, Zai-Shun Jin, Ru-yi Zheng, Tadashi Yoshino
Journal:
Oncology
Oncology (2022) 100 (5): 290–302.
Published Online: 29 March 2022
... nonampullary duodenal adenocarcinoma Microsatellite instability Prognosis Immunotherapy Small bowel adenocarcinoma (SBA) is rare compared with other gastrointestinal cancers, and primary small bowel malignancies are even rarer, accounting for less than 5% of all gastrointestinal tumors [1...
Journal Articles
Subject Area:
Oncology
Oded Jacobi, Yosef Landman, Daniel Reinhorn, Oded Icht, Michal Sternschuss, Ofer Rotem, Inbar Finkel, Aaron M. Allen, Elizabeth Dudnik, Daniel A. Goldstein, Alona Zer
Journal:
Oncology
Oncology (2021) 99 (9): 555–561.
Published Online: 09 July 2021
... patient’s gut flora composition toward bacterial strains that may cause better responses to immunotherapy [4, 21 , 22 ]. Diabetes and cancer are both multifaceted disease processes that interweave together with multiple common factors (such as clinical risk factors and signaling pathways) [9- 22...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (2021) 99 (5): 310–317.
Published Online: 09 March 2021
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Fibrolamellar carcinoma 5-FU Interferon Nivolumab Immunotherapy With fewer than 200 new cases per year worldwide, fibrolamellar carcinoma (FLC) is an extremely...
Journal Articles
Subject Area:
Oncology
Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Hiroshi Yamamoto, Tomonobu Koizumi, Masayuki Hanaoka
Journal:
Oncology
Oncology (2021) 99 (5): 271–279.
Published Online: 25 February 2021
...Kei Sonehara; Kazunari Tateishi; Taisuke Araki; Masamichi Komatsu; Hiroshi Yamamoto; Tomonobu Koizumi; Masayuki Hanaoka Purpose: The development of immune-related adverse events (irAEs) in patients undergoing immunotherapy has been reported to be a favorable prognostic factor in several studies. We...
Journal Articles
Subject Area:
Oncology
Joseph J. Zhao, Nesaretnam Barr Kumarakulasinghe, Vaishnavi Muthu, Matilda Lee, Robert Walsh, Jia Li Low, Joan Choo, Hon Lyn Tan, Wan Qin Chong, Yvonne Ang, Gloria Chan, Wei Peng Yong, Yiqing Huang, Natalie Ngoi, Alvin Wong
Journal:
Oncology
Oncology (2021) 99 (3): 192–202.
Published Online: 13 January 2021
...-dosage nivolumab regimen. [email protected] 2 09 2020 23 09 2020 13 1 2021 Renal cell carcinoma Nivolumab Immunotherapy Programmed cell death protein 1 inhibitor Table 2. Survival outcomes Fig. 1. Kaplan-Meier curves and risk tables stratified...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (2020) 98 (11): 749–754.
Published Online: 14 July 2020
... as an intravenous formulation as well as an oral formulation, with response rates of 6–12% in chemorefractory disease and 15–37% in chemosensitive disease. Immunotherapy has recently been approved as a first-line agent in metastatic SCLC in combination with chemotherapy. It is also approved as a third-line agent...
1